Need help finding what you are looking for?
Contact Us
PUBLISHER: Grand View Research | PRODUCT CODE: 1813942
PUBLISHER: Grand View Research | PRODUCT CODE: 1813942
Biomarker-based Immunoassays Market Size, Share & Trends Analysis Report By Sample (Blood, Saliva, Tissue, Urine) By Product (Reagents & Kits, Consumables), By Biomarker, By Diseases, By End-use, By Region, And Segment Forecasts, 2025 - 2033
PUBLISHED:
PAGES: 150 Pages
DELIVERY TIME: 2-10 business days
SELECT AN OPTION
Biomarker-based Immunoassays Market Summary
The global biomarker-based immunoassays market size was valued at USD 5.15 billion in 2024 and is expected to reach USD 8.33 billion by 2033, growing at a CAGR of 5.4% from 2025 to 2033. The market growth is fueled by the rising global burden of chronic diseases such as cancer, cardiovascular disorders, and neurological conditions, which require precise and early diagnostic tools.
Increasing demand for personalized medicine has driven clinicians and pharmaceutical companies to adopt biomarker-guided strategies, where immunoassays play a central role in both disease detection and therapeutic monitoring. The increasing reliance on companion diagnostics, along with regulatory support for biomarker-driven disease development, has solidified immunoassays as an essential technology in modern healthcare. Additionally, public and private investments in translational research and clinical diagnostics have sped up adoption across hospitals, laboratories, and academic institutions.
Technological advancements are also reshaping the scope of the market, with multiplexing platforms, high-throughput analyzers, and next-generation immunoassay systems enabling the simultaneous detection of multiple biomarkers with enhanced sensitivity and specificity. The integration of artificial intelligence (AI) and machine learning (ML) into biomarker-based testing improves data interpretation, while liquid biopsy-based immunoassays offer less invasive options for oncology and neurology diagnostics. Companies are also developing reagents and kits tailored for predictive and prognostic biomarkers, which are increasingly valuable in precision medicine. These innovations not only enhance diagnostic accuracy but also reduce turnaround times, making biomarker immunoassays more accessible and clinically relevant.
Global Biomarker-based Immunoassays Market Report Segmentation
This report forecasts revenue growth and provides an analysis on the latest trends in each of the sub-segments from 2021 to 2033. For the purpose of this report, Grand View Research has segmented the biomarker-based immunoassays market on the basis sample, product, biomarkers, diseases, end-use, and region:
- Sample Outlook (Revenue, USD Million, 2021 - 2033)
- Blood
- Tissue
- Urine
- Saliva
- Product Outlook (Revenue, USD Million, 2021 - 2033)
- Consumables
- Instruments/ Analyzers
- Reagent & Kits
- Services
- Biomarker Outlook (Revenue, USD Million, 2021 - 2033)
- Safety & toxicity biomarkers
- Efficacy & Pharmacodynamic Biomarkers
- Predictive & Prognostic Biomarkers
- Surrogate/Exploratory Biomarkers
- Diseases Outlook (Revenue, USD Million, 2021 - 2033)
- Cancer
- Cardiovascular Diseases
- Neurological Diseases
- Immunological Diseases
- Others
- End-use Outlook (Revenue, USD Million, 2021 - 2033)
- Hospitals & Clinics
- Diagnostic Laboratories
- Research & Academic Institutes
- Others
- Regional Outlook (Revenue, USD Million, 2021 - 2033)
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- UK
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
- Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
- Latin America
- Brazil
- Argentina
- Middle East and Africa (MEA)
- South Africa
- Saudi Arabia
- UAE
- Kuwait
Product Code: GVR-4-68040-722-5
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.2. Market Definitions
- 1.2.1. Sample Segment
- 1.2.2. Product Segment
- 1.2.3. Biomarker Segment
- 1.2.4. Diseases Segment
- 1.2.5. End Use Segment
- 1.3. Information analysis
- 1.3.1. Market formulation & data visualization
- 1.4. Data validation & publishing
- 1.5. Information Procurement
- 1.5.1. Primary Research
- 1.6. Information or Data Analysis
- 1.7. Market Formulation & Validation
- 1.8. Market Biomarkerl
- 1.9. Total Market: CAGR Calculation
- 1.10. Objectives
- 1.10.1. Objective 1
- 1.10.2. Objective 2
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Snapshot
- 2.3. Competitive Insights Landscape
Chapter 3. Global Biomarker-Based Immunoassays Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook.
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.1.1. Rising demand for precision medicine and personalized therapies
- 3.2.1.2. Increasing prevalence of chronic and infectious diseases
- 3.2.1.3. Technological advancements in immunoassay platforms
- 3.2.2. Market restraint analysis
- 3.2.2.1. High cost of advanced biomarker assays and platforms
- 3.2.1. Market driver analysis
- 3.3. Global Biomarker-Based Immunoassays Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.2. PESTEL Analysis
Chapter 4. Global Biomarker-Based Immunoassays Market: Sample Estimates & Trend Analysis
- 4.1. Segment Dashboard
- 4.2. Global Biomarker-Based Immunoassays Market Sample Movement Analysis
- 4.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by sample, 2018 to 2030 (USD Million)
- 4.4. Blood
- 4.4.1. Blood market estimates and forecasts 2021 to 2033 (USD Million)
- 4.5. Tissue
- 4.5.1. Tissue market estimates and forecasts 2021 to 2033 (USD Million)
- 4.6. Saliva
- 4.6.1. Saliva market estimates and forecasts 2021 to 2033 (USD Million)
- 4.7. Urine
- 4.7.1. Urine market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 5. Global Biomarker-Based Immunoassays Market: Product Estimates & Trend Analysis
- 5.1. Segment Dashboard
- 5.2. Global Biomarker-Based Immunoassays Market Product Movement Analysis
- 5.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by product, 2021 to 2033 (USD Million)
- 5.4. Consumables
- 5.4.1. Consumables market estimates and forecasts 2021 to 2033 (USD Million)
- 5.5. Instruments/Analyzers
- 5.5.1. Instruments/Analyzers market estimates and forecasts 2021 to 2033 (USD Million)
- 5.6. Reagent & Kits
- 5.6.1. Reagent & kits market estimates and forecasts 2021 to 2033 (USD Million)
- 5.7. Services
- 5.7.1. Services market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 6. Global Biomarker-Based Immunoassays Market: Biomarker Estimates & Trend Analysis
- 6.1. Segment Dashboard
- 6.2. Global Biomarker-Based Immunoassays Market Biomarker Movement Analysis
- 6.3. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by biomarkers, 2021 to 2033 (USD Million)
- 6.4. Safety & toxicity biomarkers
- 6.4.1. Safety & toxicity biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
- 6.5. Efficacy & Pharmacodynamic Biomarkers
- 6.5.1. Efficacy & Pharmacodynamic Biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
- 6.6. Predictive & Prognostic Biomarkers
- 6.6.1. Predictive & prognostic biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
- 6.7. Surrogate/Exploratory Biomarkers
- 6.7.1. Surrogate/exploratory biomarkers market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 7. Global Biomarker-Based Immunoassays Market: Diseases Estimates & Trend Analysis
- 7.1. Segment Dashboard
- 7.2. Global Biomarker-Based Immunoassays Market Diseases Movement Analysis
- 7.2.1. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by diseases, 2021 to 2033 (USD Million)
- 7.3. Cancer
- 7.3.1. Cancer market estimates and forecasts 2021 to 2033 (USD Million)
- 7.4. Cardiovascular Diseases
- 7.4.1. Cardiovascular diseases market estimates and forecasts 2021 to 2033 (USD Million)
- 7.5. Neurological Diseases
- 7.5.1. Neurological diseases market estimates and forecasts 2021 to 2033 (USD Million)
- 7.6. Immunological Diseases
- 7.6.1. Immunological diseases testing market estimates and forecasts 2021 to 2033 (USD Million)
- 7.7. Others
- 7.7.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 8. Global Biomarker-Based Immunoassays Market: End Use Estimates & Trend Analysis
- 8.1. Segment Dashboard
- 8.2. Global Biomarker-Based Immunoassays Market End Use Movement Analysis
- 8.2.1. Global Biomarker-Based Immunoassays Market Size & Trend Analysis, by End Use, 2021 to 2033 (USD Million)
- 8.3. Hospitals & Clinics
- 8.3.1. Hospitals and clinics market estimates and forecasts 2021 to 2033 (USD Million)
- 8.4. Diagnostic Laboratories
- 8.4.1. Diagnostic Laboratories market estimates and forecasts 2021 to 2033 (USD Million)
- 8.5. Research & Academic Institutes
- 8.5.1. Research & Academic Institutes market estimates and forecasts 2021 to 2033 (USD Million)
- 8.6. Others
- 8.6.1. Others market estimates and forecasts 2021 to 2033 (USD Million)
Chapter 9. Biomarker-Based Immunoassays Market: Regional Estimates & Trend Analysis
- 9.1. Regional Dashboard
- 9.2. Market Size, & Forecasts Trend Analysis, 2021 to 2033:
- 9.3. North America
- 9.3.1. U.S.
- 9.3.1.1. Key country dynamics
- 9.3.1.2. Regulatory framework/ reimbursement structure
- 9.3.1.3. Competitive scenario
- 9.3.1.4. U.S. market estimates and forecasts 2021 to 2033 (USD Million)
- 9.3.2. Canada
- 9.3.2.1. Key country dynamics
- 9.3.2.2. Regulatory framework/ reimbursement structure
- 9.3.2.3. Competitive scenario
- 9.3.2.4. Canada market estimates and forecasts 2021 to 2033 (USD Million)
- 9.3.3. Mexico
- 9.3.3.1. Key country dynamics
- 9.3.3.2. Regulatory framework/ reimbursement structure
- 9.3.3.3. Competitive scenario
- 9.3.3.4. Mexico market estimates and forecasts 2021 to 2033 (USD Million)
- 9.3.1. U.S.
- 9.4. Europe
- 9.4.1. UK
- 9.4.1.1. Key country dynamics
- 9.4.1.2. Regulatory framework/ reimbursement structure
- 9.4.1.3. Competitive scenario
- 9.4.1.4. UK market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.2. Germany
- 9.4.2.1. Key country dynamics
- 9.4.2.2. Regulatory framework/ reimbursement structure
- 9.4.2.3. Competitive scenario
- 9.4.2.4. Germany market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.3. France
- 9.4.3.1. Key country dynamics
- 9.4.3.2. Regulatory framework/ reimbursement structure
- 9.4.3.3. Competitive scenario
- 9.4.3.4. France market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.4. Italy
- 9.4.4.1. Key country dynamics
- 9.4.4.2. Regulatory framework/ reimbursement structure
- 9.4.4.3. Competitive scenario
- 9.4.4.4. Italy market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.5. Spain
- 9.4.5.1. Key country dynamics
- 9.4.5.2. Regulatory framework/ reimbursement structure
- 9.4.5.3. Competitive scenario
- 9.4.5.4. Spain market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.6. Norway
- 9.4.6.1. Key country dynamics
- 9.4.6.2. Regulatory framework/ reimbursement structure
- 9.4.6.3. Competitive scenario
- 9.4.6.4. Norway market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.7. Sweden
- 9.4.7.1. Key country dynamics
- 9.4.7.2. Regulatory framework/ reimbursement structure
- 9.4.7.3. Competitive scenario
- 9.4.7.4. Sweden market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.8. Denmark
- 9.4.8.1. Key country dynamics
- 9.4.8.2. Regulatory framework/ reimbursement structure
- 9.4.8.3. Competitive scenario
- 9.4.8.4. Denmark market estimates and forecasts 2021 to 2033 (USD Million)
- 9.4.1. UK
- 9.5. Asia Pacific
- 9.5.1. Japan
- 9.5.1.1. Key country dynamics
- 9.5.1.2. Regulatory framework/ reimbursement structure
- 9.5.1.3. Competitive scenario
- 9.5.1.4. Japan market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.2. China
- 9.5.2.1. Key country dynamics
- 9.5.2.2. Regulatory framework/ reimbursement structure
- 9.5.2.3. Competitive scenario
- 9.5.2.4. China market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.3. India
- 9.5.3.1. Key country dynamics
- 9.5.3.2. Regulatory framework/ reimbursement structure
- 9.5.3.3. Competitive scenario
- 9.5.3.4. India market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.4. Australia
- 9.5.4.1. Key country dynamics
- 9.5.4.2. Regulatory framework/ reimbursement structure
- 9.5.4.3. Competitive scenario
- 9.5.4.4. Australia market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.5. South Korea
- 9.5.5.1. Key country dynamics
- 9.5.5.2. Regulatory framework/ reimbursement structure
- 9.5.5.3. Competitive scenario
- 9.5.5.4. South Korea market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.6. Thailand
- 9.5.6.1. Key country dynamics
- 9.5.6.2. Regulatory framework/ reimbursement structure
- 9.5.6.3. Competitive scenario
- 9.5.6.4. Thailand market estimates and forecasts 2021 to 2033 (USD Million)
- 9.5.1. Japan
- 9.6. Latin America
- 9.6.1. Brazil
- 9.6.1.1. Key country dynamics
- 9.6.1.2. Regulatory framework/ reimbursement structure
- 9.6.1.3. Competitive scenario
- 9.6.1.4. Brazil market estimates and forecasts 2021 to 2033 (USD Million)
- 9.6.2. Argentina
- 9.6.2.1. Key country dynamics
- 9.6.2.2. Regulatory framework/ reimbursement structure
- 9.6.2.3. Competitive scenario
- 9.6.2.4. Argentina market estimates and forecasts 2021 to 2033 (USD Million)
- 9.6.1. Brazil
- 9.7. MEA
- 9.7.1. South Africa
- 9.7.1.1. Key country dynamics
- 9.7.1.2. Regulatory framework/ reimbursement structure
- 9.7.1.3. Competitive scenario
- 9.7.1.4. South Africa market estimates and forecasts 2021 to 2033 (USD Million)
- 9.7.2. Saudi Arabia
- 9.7.2.1. Key country dynamics
- 9.7.2.2. Regulatory framework/ reimbursement structure
- 9.7.2.3. Competitive scenario
- 9.7.2.4. Saudi Arabia market estimates and forecasts 2021 to 2033 (USD Million)
- 9.7.3. UAE
- 9.7.3.1. Key country dynamics
- 9.7.3.2. Regulatory framework/ reimbursement structure
- 9.7.3.3. Competitive scenario
- 9.7.3.4. UAE market estimates and forecasts 2021 to 2033 (USD Million)
- 9.7.4. Kuwait
- 9.7.4.1. Key country dynamics
- 9.7.4.2. Regulatory framework/ reimbursement structure
- 9.7.4.3. Competitive scenario
- 9.7.4.4. Kuwait market estimates and forecasts 2021 to 2033 (USD Million)
- 9.7.1. South Africa
Chapter 10. Competitive Landscape
- 10.1. Company/Competition Categorization
- 10.2. Strategy Mapping
- 10.3. Company Market Share Analysis, 2024
- 10.4. List of Key Certification Providers/Scheme Owners
- 10.5. Company Profiles/Listing
- 10.5.1. F. Hoffmann-La Roche AG
- 10.5.1.1. Company overview
- 10.5.1.2. Financial performance
- 10.5.1.3. Product benchmarking
- 10.5.1.4. Strategic initiatives
- 10.5.2. Abbott
- 10.5.2.1. Company overview
- 10.5.2.2. Financial performance
- 10.5.2.3. Product benchmarking
- 10.5.2.4. Strategic initiatives
- 10.5.3. Thermo Fisher Scientific Inc
- 10.5.3.1. Company overview
- 10.5.3.2. Financial performance
- 10.5.3.3. Product benchmarking
- 10.5.3.4. Strategic initiatives
- 10.5.4. Eurofins Scientific
- 10.5.4.1. Company overview
- 10.5.4.2. Financial performance
- 10.5.4.3. Product benchmarking
- 10.5.4.4. Strategic initiatives
- 10.5.5. QIAGEN
- 10.5.5.1. Company overview
- 10.5.5.2. Financial performance
- 10.5.5.3. Product benchmarking
- 10.5.5.4. Strategic initiatives
- 10.5.6. Bio-Rad Laboratories, Inc.
- 10.5.6.1. Company overview
- 10.5.6.2. Financial performance
- 10.5.6.3. Product benchmarking
- 10.5.6.4. Strategic initiatives
- 10.5.7. Siemens Healthineers AG
- 10.5.7.1. Company overview
- 10.5.7.2. Financial performance
- 10.5.7.3. Product benchmarking
- 10.5.7.4. Strategic initiatives
- 10.5.8. Merck KGaA
- 10.5.8.1. Company overview
- 10.5.8.2. Financial performance
- 10.5.8.3. Product benchmarking
- 10.5.8.4. Strategic initiatives
- 10.5.9. PerkinElmer Inc.
- 10.5.9.1. Company overview
- 10.5.9.2. Financial performance
- 10.5.9.3. Product benchmarking
- 10.5.9.4. Strategic initiatives
- 10.5.10. Agilent Technologies, Inc.
- 10.5.10.1. Company overview
- 10.5.10.2. Financial performance
- 10.5.10.3. Product benchmarking
- 10.5.10.4. Strategic initiatives
- 10.5.1. F. Hoffmann-La Roche AG
Product Code: GVR-4-68040-722-5
List of Tables
- Table 1 List of Secondary Sources
- Table 2 List of Abbreviation
- Table 3 U.S. biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 4 U.S. biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 5 U.S. biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 6 U.S. biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 7 U.S. biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 8 North America biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
- Table 9 North America biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 10 North America biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 11 North America biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 12 North America biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 13 North America biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 14 Canada biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 15 Canada biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 16 Canada biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 17 Canada biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 18 Canada biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 19 Mexico biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 20 Mexico biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 21 Mexico biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 22 Mexico biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 23 Mexico biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 24 Europe biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
- Table 25 Europe biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 26 Europe biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 27 Europe biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 28 Europe biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 29 Europe biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 30 UK biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 31 UK biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 32 UK biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 33 UK biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 34 UK biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 35 Germany biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 36 Germany biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 37 Germany biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 38 Germany biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 39 Germany biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 40 France biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 41 France biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 42 France biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 43 France biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 44 France biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 45 Italy biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 46 Italy biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 47 Italy biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 48 Italy biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 49 Italy biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 50 Spain biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 51 Spain biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 52 Spain biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 53 Spain biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 54 Spain biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 55 Denmark biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 56 Denmark biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 57 Denmark biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 58 Denmark biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 59 Denmark biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 60 Sweden biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 61 Sweden biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 62 Sweden biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 63 Sweden biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 64 Sweden biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 65 Norway biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 66 Norway biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 67 Norway biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 68 Norway biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 69 Norway biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 70 Asia Pacific biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
- Table 71 Asia Pacific biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 72 Asia Pacific biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 73 Asia Pacific biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 74 Asia Pacific biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 75 Asia Pacific biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 76 Japan biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 77 Japan biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 78 Japan biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 79 Japan biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 80 Japan biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 81 China biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 82 China biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 83 China biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 84 China biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 85 China biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 86 India biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 87 India biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 88 India biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 89 India biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 90 India biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 91 Australia biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 92 Australia biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 93 Australia biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 94 Australia biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 95 Australia biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 96 South Korea biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 97 South Korea biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 98 South Korea biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 99 South Korea biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 100 South Korea biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 101 Thailand biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 102 Thailand biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 103 Thailand biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 104 Thailand biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 105 Thailand biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 106 Latin America biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
- Table 107 Latin America biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 108 Latin America biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 109 Latin America biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 110 Latin America biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 111 Latin America biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 112 Brazil biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 113 Brazil biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 114 Brazil biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 115 Brazil biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 116 Brazil biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 117 Argentina biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 118 Argentina biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 119 Argentina biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 120 Argentina biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 121 Argentina biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 122 MEA biomarker-based immunoassays market, by region, 2021 - 2033 (USD Million)
- Table 123 MEA biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 124 MEA biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 125 MEA biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 126 MEA biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 127 MEA biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 128 South Africa biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 129 South Africa biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 130 South Africa biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 131 South Africa biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 132 South Africa biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 133 Saudi Arabia biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 134 Saudi Arabia biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 135 Saudi Arabia biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 136 Saudi Arabia biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 137 Saudi Arabia biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 138 UAE biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 139 UAE biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 140 UAE biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 141 UAE biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 142 global biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
- Table 143 Kuwait biomarker-based immunoassays market, by sample, 2021 - 2033 (USD Million)
- Table 144 Kuwait biomarker-based immunoassays market, by product, 2021 - 2033 (USD Million)
- Table 145 Kuwait biomarker-based immunoassays market, by biomarkers, 2021 - 2033 (USD Million)
- Table 146 Kuwait biomarker-based immunoassays market, by diseases, 2021 - 2033 (USD Million)
- Table 147 Kuwait biomarker-based immunoassays market, by end use, 2021 - 2033 (USD Million)
List of Figures
- Fig. 1 Global biomarker-based immunoassays market segmentation
- Fig. 2 Data analysis biomarkers
- Fig. 3 Market formulation and validation
- Fig. 4 Data validating & publishing
- Fig. 5 Market research process
- Fig. 6 Information procurement
- Fig. 7 Primary research
- Fig. 8 Value-chain-based sizing & forecasting
- Fig. 9 QFD biomarker modelling for market share assessment
- Fig. 10 Market formulation & validation
- Fig. 11 Commodity flow analysis
- Fig. 12 Market outlook
- Fig. 13 Segment snapshot-1
- Fig. 14 Segment snapshot-2
- Fig. 15 Competitive landscape snapshot
- Fig. 16 Market trends & outlook
- Fig. 17 Porter's five force analysis
- Fig. 18 PESTEL analysis
- Fig. 19 Global biomarker-based immunoassays market: Sample outlook key takeaways
- Fig. 20 Global biomarker-based immunoassays market: Sample movement analysis
- Fig. 21 Blood market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 22 Tissue market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 23 Saliva market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 24 Urine market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 25 Global biomarker-based immunoassays market: Product outlook key takeaways
- Fig. 26 Global biomarker-based immunoassays market: Product movement analysis
- Fig. 27 Consumables market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 28 Instruments/Analyzers market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 29 Reagent & kits market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 30 Services market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 31 Global biomarker-based immunoassays market: Biomarker outlook key takeaways
- Fig. 32 Global biomarker-based immunoassays market: Biomarker movement analysis
- Fig. 33 Safety & toxicity biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 34 Efficacy & pharmacodynamic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 35 Predictive & prognostic biomarkers market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 36 Surrogate/Exploratory biomarkers estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 37 Global biomarker-based immunoassays market: Biomarker outlook key takeaways
- Fig. 38 Global biomarker-based immunoassays market: Biomarker movement analysis
- Fig. 39 Cancer market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 40 Cardiovascular diseases market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 41 Neurological diseases market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 42 Immunological diseases market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 43 OtherOthers market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 44 Global biomarker-based immunoassays market: End Use outlook key takeaways
- Fig. 45 Global biomarker-based immunoassays market: End Use movement analysis
- Fig. 46 Hospitals and clinics market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 47 Diagnostic laboratories market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 48 Research & academic institutes market estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 49 Others estimates and forecasts, 2021 - 2033 (USD Million)
- Fig. 50 Biomarker-based immunoassays market: Regional outlook and key takeaways
- Fig. 51 Regional outlook, 2024 & 2030
- Fig. 52 North America
- Fig. 53 North America market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 54 U.S. key country dynamics
- Fig. 55 U.S. market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 56 Canada key country dynamics
- Fig. 57 Canada market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 58 Europe
- Fig. 59 Europe market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 60 UK key country dynamics
- Fig. 61 UK market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 62 Germany
- Fig. 63 Germany market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 64 France key country dynamics
- Fig. 65 France market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 66 Italy key country dynamics
- Fig. 67 Italy market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 68 Spain key country dynamics
- Fig. 69 Spain market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 70 Denmark key country dynamics
- Fig. 71 Denmark market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 72 Sweden key country dynamics
- Fig. 73 Sweden market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 74 Norway key country dynamics
- Fig. 75 Norway market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 76 Asia-Pacific
- Fig. 77 Asia-Pacific market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 78 Japan key country dynamics
- Fig. 79 Japan market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 80 China key country dynamics
- Fig. 81 China market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 82 India key country dynamics
- Fig. 83 India market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 84 South Korea key country dynamics
- Fig. 85 South Korea market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 86 Australia key country dynamics
- Fig. 87 Australia market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 88 Thailand key country dynamics
- Fig. 89 Thailand market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 90 Latin America
- Fig. 91 Latin America market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 92 Brazil key country dynamics
- Fig. 93 Brazil market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 94 Mexico key country dynamics
- Fig. 95 Mexico market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 96 Argentina key country dynamics
- Fig. 97 Argentina market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 98 Middle East & Africa
- Fig. 99 MEA market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 100 South Africa key country dynamics
- Fig. 101 South Africa market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 102 Saudi Arabia key country dynamics
- Fig. 103 Saudi Arabia market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 104 UAE key country dynamics
- Fig. 105 UAE market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 106 Kuwait key country dynamics
- Fig. 107 Kuwait market estimates and forecast, 2021 - 2033 (USD Million)
- Fig. 108 Market differentiators
- Fig. 109 Key company market share analysis, 2024
Have a question?
SELECT AN OPTION
Have a question?
Questions? Please give us a call or visit the contact form.